Medical Reporting News
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
-
Australian Medical Micro Screw Innovation Makes World Debut in 30 Jan 2019 Brisbane Operation
An innovative Australian micro screw created to help significantly reduce complications in the management of orthopaedic injuries and the fixing of fractures in the hand and wrist will be used in a world-first operation in Brisbane by internationally-renowned hand surgeon Dr Greg Couzens on Wednesday 30 January. The Field Micro Screw by Brisbane med-tech start-up Field Orthopaedics has already ...
-
Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...
-
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a ...
-
FDA Grants Saranas DeNovo Designation for the Early Bird® Bleed Monitoring System
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been granted de novo classification by the U.S. Food and Drug Administration (FDA) for the Early Bird Bleed Monitoring System. According to a recent study of over 17,000 large-bore transcatheter interventions ...
-
Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders
TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company’s Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of ...
-
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 23, 2022, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to four individuals entering into employment with the Company. The equity awards ...
-
Titan Medical Reports Financial Results for the First Quarter 2022
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. “The entire team is focused on driving performance and progress supporting our IDE ...
-
AVITA Medical Reports First Quarter 2022 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022. Financial Highlights and Recent Updates: Reported commercial revenue, ...
-
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
-
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 ...
-
Microbot Medical Achieves Significant Regulatory Milestone for the LIBERTY Robotic System; Files FDA Pre-Submission Package for Regulatory Pathway
HINGHAM, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- The operational momentum that Microbot Medical Inc. (Nasdaq: MBOT) experienced at the end of 2021 has continued well into the 2022 first quarter. The Company filed its pre-submission package for the LIBERTY® Robotic System with the U.S. Food and Drug Administration (FDA), addressing the regulatory pathway for the LIBERTY® Robotic System. ...
-
Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results
Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. The Company also announced that Leslie Trigg has been appointed Chair of the Board of Directors in ...
-
Outset Medical to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 16, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern ...
-
Esocap Featured In Fierce Pharma
“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using ...
By EsoCap AG
-
Outset Medical Launches Inaugural ESG Report
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the release of its inaugural Environmental, Social, and Governance (ESG) report highlighting its ESG-related programs, priorities, goals, and performance. “At Outset, our ESG journey is rooted in our ...
-
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver ...
-
Why do you require to have a Liver transplant?
If anyhow, your liver stops working properly, you may need a liver transplant. Liver Transplant India is generally recommended if you have a last-stage liver disease, which is chronic liver failure. This is a life-threatening and serious liver disease, and this is be caused by many liver conditions. For instance, cirrhosis is one of the common causes of end-stage liver disease. It is one of the ...
-
Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking clinical trials presentation was delivered by Dr. Tom De ...
-
Alleviant Medical Announces Presentation of Clinical Data at American College of Cardiology and EuroPCR Conferences
Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved ejection fraction (HFpEF). The Alleviant System is a novel transcatheter device for the creation of a therapeutic interatrial shunt without a permanent ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you